PharmaShots’ Key Highlights of First Quarter 2021

The first quarter of 2021 highlights new approvals, M&A, and the clinical data of COVID-19 vaccines. The companies expand their working in COVID-19 by targeting South African & Brazil variants along with other emerging variants Starting with the latest acquisition, Amgen acquired Five Prime for $1.9B, Jazz acquired JW while Boston acquired Preventice. This quarter…

ByRidhi RastogiApril 4, 2021

INSIGHTS+

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012 The Breakthrough Designation is granted to the drug candidates as monotherapy or in combination with other drugs intended to treat serious or life-threatening diseases and has shown substantial improvement over available…

BySenior EditorMarch 11, 2021

TOP 20

Top 20 Life Sciences Deals of 2020 by Total Deal Value

Life sciences companies are gearing up to enter new markets as they look to secure their positions after a spate of M&A- licensing- and research partnerships in 2020 Artios partnered with Merck with an option to license up to 8 oncology programs proving to be the highest valued deal of 2020 with a total deal…

ByPrince GiriJanuary 22, 2021

INSIGHTS+

Insights+: COVID-19 Healthcare News Monthly Updates – January 2020

Shots: Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019 PharmaShots is keeping a track of all of the important updates in the Lifesciences sector…

BySenior EditorDecember 31, 2020

INSIGHTS+

Insights+: COVID-19 Healthcare News Monthly Updates – November 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it Life sciences companies are putting all of their efforts into finding a treatment or developing a vaccine for this disease PharmaShots is keeping a track of all of the important updates in the Life-sciences…

BySenior EditorNovember 26, 2020

TOP 20

Top 20 Immunology Companies Based 2019 Immunology Segment Revenue

Immunology is an important branch of science which deals with the study of the immune system. The immune system is a highly regulated and balanced system and when the balance is disturbed- the disease can result. A lot of this work has importance in the development of new therapies and treatments that can handle or…

ByPrince GiriOctober 22, 2020

VIEWPOINTS

PharmaShots Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insights on Baricitinib

In a recent interview with PharmaShots, Dr. Lotus Mallbris, the Vice President of Immunology Development at Eli Lilly shares her insights and highlights on Baricitinib. Shots: If approved, Baricitinib could be the first JAK inhibitor in the EU for adults with moderate to severe AD. EC's decision is expected in the next one-two months. Lilly is evaluating Baricitinib for SLE, for which…

BySenior EditorOctober 12, 2020

TOP 20

Top 20 Oncology Companies by Total Products of 2019

To remain successful in the oncology market- change is now a key to adapt to this altering market dynamics. A recent development in science and technology platforms are likely to grow faster for cancer treatment in comparison to other therapy areas. However- despite robust levels of pipeline activity- oncology remains a challenging area for research…

ByPrince GiriSeptember 24, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in June 2020

The US FDA has approved multiple NDAs and BLAs in Jun 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 51 novel products so far in 2020, including 8 in Jun 2020. Additionally,…

BySenior EditorJuly 24, 2020

INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2020

The second quarter of 2020 has ended with big approvals in pharma and biotech industry. Moving with the latest approval of Roche's Phesgo and Enspryng & Zogenix's Fintepla. Highlights of the quarter is COVID-19 as the development of vaccines and drugs were on peak. Celltrion evaluated Remsima (biosimilar, infliximab) against COVID-19 in the UK. The…

BySenior EditorJuly 7, 2020

PharmaShots’ Key Highlights of First Quarter 2021

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Top 20 Life Sciences Deals of 2020 by Total Deal Value

Insights+: COVID-19 Healthcare News Monthly Updates – January 2020

Insights+: COVID-19 Healthcare News Monthly Updates – November 2020

Top 20 Immunology Companies Based 2019 Immunology Segment Revenue

PharmaShots Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insights on Baricitinib

Top 20 Oncology Companies by Total Products of 2019

Insights+: The US FDA New Drug Approvals in June 2020

PharmaShots’ Key Highlights of Second Quarter 2020

Contact US

FOLLOW US